

StrataGraft is the first burn treatment to be granted the NTAP—effective October 1, 2021¹

What is NTAP?^{2,3}

The Centers for Medicare & Medicaid Services (CMS) created the NTAP to help ensure hospitals do not incur significant reimbursement shortfalls when adopting innovative new technologies.

NTAP is an additional payment on top of the Medicare Severity Diagnosis Related Group (MS-DRG) or TRICARE DRG reimbursement.

Why was StrataGraft granted the NTAP?¹

StrataGraft was granted the NTAP by CMS because it meets the 3 criteria for eligibility below. CMS noted that:

- **Newness:** StrataGraft has a “*unique mechanism of action*”
- **Cost:** The average standardized cost for cases involving StrataGraft “*exceeds the case-weighted threshold amount*”
- **Substantial clinical improvement:**
 - StrataGraft “*facilitates durable wound closure without the need for skin harvest and/or autograft*”
 - StrataGraft “*reduces the necessity for additional healing sites as well as the additional scarring and pain that come along with [them]*”

How to code for add-on payment^{1,4}

The International Classification of Diseases 10th Revision Procedure Coding System (ICD-10-PCS) code for StrataGraft is XHRPXF7 and is effective on October 1, 2021. Hospitals can report this code on claim forms for procedures related to StrataGraft to receive the add-on payment for eligible inpatient cases.

DETAILS OF NTAP

Eligible facilities^{1,3}	<ul style="list-style-type: none"> • Acute care hospitals participating in the inpatient prospective payment system are eligible • Hospitals under the TRICARE program are eligible
Qualified patients³	<ul style="list-style-type: none"> • Traditional Medicare and dual-eligible (Medicare-Medicaid) fee-for-service patients or TRICARE patients whose case totals exceed the MS-DRG rate payment are qualified
Add-on payment¹	<ul style="list-style-type: none"> • The NTAP is limited to the lesser of 65% of the cost of the new technology or 65% of the amount by which the cost of the case exceeds the MS-DRG payment • The maximum add-on payment for StrataGraft is \$44,200 for fiscal year (FY) 2022
Effective date¹	<ul style="list-style-type: none"> • October 1, 2021, to September 30, 2022 (FY 2022)
Duration¹	<ul style="list-style-type: none"> • NTAP is approved for a minimum of 2 years and no more than 3 years; the maximum add-on payment amount is reassessed annually
ICD-10-PCS code^{1,4}	<ul style="list-style-type: none"> • XHRPXF7 (Replacement of skin with bioengineered allogeneic construct, external approach, new technology group 7)

INDICATION

StrataGraft[®] is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

- Do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin.



For more information, visit [StrataGraft.com](https://www.stratagraft.com) or call 1-877-647-2239 for additional support

The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Mallinckrodt concerning levels of reimbursement, payment, or charge. Similarly, all codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Mallinckrodt that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payer. We strongly recommend that you consult your payer organization with regard to its reimbursement policies. **You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes.**

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- StrataGraft contains glycerin. Avoid glycerin in patients with known sensitivity (irritant reaction) to glycerin.
- Severe hypersensitivity reactions may occur. Monitor for both early and late symptoms and signs of hypersensitivity reaction following StrataGraft application, and treat according to standard medical practice.
- StrataGraft contains cells from human donors and may transmit infectious diseases or infectious agents, eg, viruses, bacteria, or other pathogens, including the agent that causes transmissible spongiform encephalopathy (TSE, also known as Creutzfeldt-Jakob disease [CJD or variant CJD]).

StrataGraft is a xenotransplantation product because of an historic exposure of the keratinocyte cells to well-characterized mouse cells. The cell banks have been tested and found to be free of detectable adventitious agents, and mouse cells are not used in the manufacture of StrataGraft; however, these measures do not entirely eliminate the risk of transmitting infectious diseases and disease agents.

Transmission of infectious diseases or agents by StrataGraft has not been reported.

- Because StrataGraft is a xenotransplantation product, StrataGraft recipients should not donate whole blood, blood components, plasma, leukocytes, tissues, breast milk, ova, sperm, or other body parts for use in humans.

Adverse Reactions

- The most common adverse reactions (incidence $\geq 2\%$) were itching (pruritus), blisters, hypertrophic scar, and impaired healing. Other adverse events reported are included in the full Prescribing Information.

Pediatric Use

- The safety and effectiveness of StrataGraft in pediatric patients (<18 years) have not been established.

Please see additional Important Safety Information on previous page and full [Prescribing Information](#).

References: **1.** Medicare program; hospital inpatient prospective payment system for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2022 rates; hospitals' resident caps for graduate medical education payment purposes; quality reporting requirements for specific providers and for ambulatory surgical centers. *Fed Regist.* 2021;86(154):45079-45090. To be codified at 42 CFR 412, 413. **2.** New medical services and new technologies. Centers for Medicare & Medicaid Services. Updated August 13, 2021. Accessed August 20, 2021. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelInpatientPPS/newtech>. **3.** Hospital reimbursement - TRICARE diagnosis related group (DRG)-based payment system (new technology add-on payments (NTAPs)). In: *TRICARE Reimbursement Manual 6010.61-M*. Military Health System; 2021:chap 6. Accessed August 20, 2021. <https://manuals.health.mil/pages/DisplayManualHtmlFile/2021-04-09/AsOf/TR15/C6S11.html>. **4.** 2022 ICD-10-PCS. Centers for Medicare & Medicaid Services. Updated June 4, 2021. Accessed August 20, 2021. <https://www.cms.gov/medicare/icd-10/2022-icd-10-pcs>.